Walleye Capital LLC Buys Shares of 69,452 Vaxcyte, Inc. (NASDAQ:PCVX)

Walleye Capital LLC bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVXGet Rating) in the first quarter, Holdings Channel reports. The fund bought 69,452 shares of the company’s stock, valued at approximately $1,677,000.

Several other hedge funds and other institutional investors also recently modified their holdings of PCVX. Advisor Group Holdings Inc. purchased a new position in shares of Vaxcyte during the fourth quarter worth about $53,000. Citigroup Inc. grew its holdings in shares of Vaxcyte by 83.7% during the fourth quarter. Citigroup Inc. now owns 46,433 shares of the company’s stock worth $1,105,000 after purchasing an additional 21,159 shares in the last quarter. Rafferty Asset Management LLC grew its holdings in shares of Vaxcyte by 64.7% during the fourth quarter. Rafferty Asset Management LLC now owns 46,256 shares of the company’s stock worth $1,100,000 after purchasing an additional 18,177 shares in the last quarter. Ghost Tree Capital LLC grew its holdings in shares of Vaxcyte by 56.3% during the fourth quarter. Ghost Tree Capital LLC now owns 250,000 shares of the company’s stock worth $5,948,000 after purchasing an additional 90,000 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in shares of Vaxcyte during the fourth quarter worth about $2,317,000. Hedge funds and other institutional investors own 86.74% of the company’s stock.

Vaxcyte Trading Down 7.4 %

Shares of NASDAQ PCVX opened at $26.13 on Friday. The business has a 50-day moving average of $25.69 and a 200-day moving average of $24.24. The firm has a market capitalization of $1.55 billion, a price-to-earnings ratio of -10.33 and a beta of 0.39. Vaxcyte, Inc. has a 12 month low of $16.78 and a 12 month high of $29.73.

Insider Buying and Selling

In related news, CEO Grant Pickering sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 26th. The stock was sold at an average price of $27.44, for a total value of $274,400.00. Following the completion of the sale, the chief executive officer now owns 162,830 shares in the company, valued at approximately $4,468,055.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Grant Pickering sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 26th. The stock was sold at an average price of $27.44, for a total value of $274,400.00. Following the completion of the sale, the chief executive officer now owns 162,830 shares in the company, valued at approximately $4,468,055.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Paul Sauer sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the sale, the senior vice president now owns 20,687 shares of the company’s stock, valued at approximately $517,175. The disclosure for this sale can be found here. Insiders sold 102,840 shares of company stock worth $2,549,513 in the last quarter. 13.70% of the stock is owned by insiders.

About Vaxcyte

(Get Rating)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia.

See Also

Want to see what other hedge funds are holding PCVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxcyte, Inc. (NASDAQ:PCVXGet Rating).

Institutional Ownership by Quarter for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.